Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: rationale and design

BACKGROUND: Ischemic stroke and other vascular outcomes occur in 10–20% of patients in the 3 months following a TIA or minor ischemic stroke, and many are disabling. The highest risk period for these outcomes is the early hours and days immediately following the ischemic event. Aspirin is the most c...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Int J Stroke
Glavni autori: Johnston, S. Claiborne, Easton, J. Donald, Farrant, Mary, Barsan, William, Battenhouse, Holly, Conwit, Robin, Dillon, Catherine, Elm, Jordan, Lindblad, Anne, Morgenstern, Lewis, Poisson, Sharon N., Palesch, Yuko
Format: Artigo
Jezik:Inglês
Izdano: 2013
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4412261/
https://ncbi.nlm.nih.gov/pubmed/23879752
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijs.12129
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items